AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 91 min read$URGN

Degnan Chris sold $81K of URGN

Degnan Chris (Chief Financial Officer) sold 2,202 shares of UroGen Pharma Ltd. (URGN) at $36.69 on 2026-10-08.

Original reporting
SEC EDGAR · Degnan Chris
Published Oct 9, 2026, 4:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$URGN
Bearish
medium confidence
Mentioned
$URGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$URGNBearishLow
01

Why it matters

The CFO's sale is a primary disclosure but the transaction size is modest, suggesting limited price impact.

02

Market read

A small insider sale that may cause slight short-term pressure but unlikely to move the stock significantly.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: after market close

Background

Form 4 filings disclose insider transactions and are used by traders to gauge potential sentiment shifts.

Company-level read

Ticker impact

$URGNBearishMedium confidence
Context

CFO Degnan Chris sold 2,202 shares of UroGen Pharma for $80,791, reducing his stake to 4,561 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell.

Evidence & confidence

A $80k sale by the CFO is a primary Form 4 filing but the amount is small relative to market cap, limiting material impact.

Market effects

Sector

Minimal impact on the biotech sector; no broader industry signal.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity in URGN.

Counterpoint

What could challenge this read

The sale could be interpreted as a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Person
    Degnan Chris

    Chief Financial Officer of UroGen Pharma Ltd.

  • Company
    UroGen Pharma Ltd.

    Biopharmaceutical company focused on oncology therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

URGN insider trading history →

Related articles

OCT 19
$URGNHighAI 8/10

UroGen Secures FDA NDA Acceptance For Investigational Bladder Cancer Therapy

UroGen Pharma (URGN) announced FDA acceptance of its NDA for UGN-103, an investigational bladder cancer treatment. The FDA set a PDUFA target action date of June 14, 2027. The NDA is backed by Phase 3 UTOPIA trial data, showing a 77.8% complete response rate at three months. UGN-103 combines RTGel hydrogel with mitomycin. URGN shares are down 2.05% at $33.85.

rttnews.com2 min
OCT 19
$URGNMedAI 8/10

FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC

The FDA accepted UroGen Pharma's NDA for UGN-103, a treatment for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, with a PDUFA target action date of June 14, 2027. The application is backed by UTOPIA trial data showing a 77.8% complete response rate at 3 months and 94.5% event-free probability at 6 months among responders. UGN-103 uses a proprietary RTGel technology with mitomycin.

onclive.com2 min
OCT 19
$URGNHighAI 8/10

UroGen Pharma Announces FDA Acceptance Of UGN-103 NDA For Review

UroGen Pharma (URGN) announced FDA acceptance of the New Drug Application for UGN-103, a treatment for recurrent low-grade bladder cancer, with a PDUFA target action date of June 14, 2027. The NDA is supported by Phase 3 UTOPIA trial data. UroGen shares rose 0.69% to $34.80 in pre-market trading.

rttnews.com1 min
OCT 19
$URGNMedAI 8/10

FDA accepts UroGen’s drug application for bladder cancer

UroGen Pharma (URGN) announced the FDA accepted its New Drug Application for UGN-103, a treatment for recurrent low-grade bladder cancer. The FDA set a target review date of June 14, 2027. The application is supported by Phase 3 trial data showing a 77.8% complete response rate at three months. UroGen holds U.S. patents for the drug through July 2044.

investing.com2 min